Table 1.
Analysis of population-patient characteristics by CD4 cell count at diagnosis
| CD4 cell count at HIV diagnosis | ||||
|---|---|---|---|---|
|
|
||||
| Factor | Level | CD4 <200 cells/µL N (%) | CD4 201–350 cells/µL N (%) | CD4 >350 cells/µL N (%) |
| Number of patients | (Total n=1202) | 245 (20) | 185 (15) | 772 (65) |
| Year of cohort enrolment | 1999–2004 | 135 (55) | 82 (44) | 280 (36) |
| 2005–2009 | 72 (29) | 56 (30) | 279 (36) | |
| 2010–2012 | 38 (16) | 47 (25) | 213 (28) | |
| Sex | Female | 14 (6) | 16 (9) | 54 (7) |
| Male | 231 (94) | 169 (91) | 718 (93) | |
| Age at cohort enrolment (years) | <30 | 18 (7) | 29 (16) | 135 (17) |
| 30–40 | 69 (28) | 58 (31) | 293 (38) | |
| 40–50 | 68 (28) | 59 (32) | 232 (30) | |
| >50 | 90 (37) | 39 (21) | 112 (15) | |
| Mode of probable HIV exposure | MSM | 144 (59) | 127 (69) | 571 (74) |
| Heterosexual | 70 (28) | 45 (24) | 146 (19) | |
| IDU | 12 (5) | 5 (3) | 30 (4) | |
| Other | 19 (8) | 8 (4) | 25 (3) | |
| Continental region of birth | Australia | 135 (55) | 110 (59) | 502 (65) |
| New Zealand/Pacific Islander | 4 (2) | 5 (3) | 21 (3) | |
| Africa | 9 (4) | 6 (3) | 8 (1) | |
| Americas | 6 (2) | 2 (1) | 9 (1) | |
| Asia | 22 (9) | 14 (8) | 42 (5) | |
| Europe | 20 (8) | 14 (8) | 41 (5) | |
| Not reported | 49 (20) | 34 (18) | 149 (19) | |
| Hepatitis B SurAg (ever) | Positive | 10 (4) | 7 (4) | 18 (2) |
| Negative | 199 (81) | 148 (80) | 598 (77) | |
| Not reported | 36 (15) | 30 (16) | 156 (20) | |
| Hepatitis C antibody (ever) | Positive | 18 (7) | 7 (4) | 59 (8) |
| Negative | 211 (86) | 165 (89) | 634 (82) | |
| Not reported | 16 (7) | 13 (7) | 79 (10) | |
| Australian state capital city setting | Capital city | 162 (66) | 126 (68) | 565 (73) |
| Non-capital city | 83 (34) | 59 (32) | 207 (27) | |
| Primary care setting | General practice | 76 (31) | 64 (35) | 327 (42) |
| Hospital clinic | 68 (28) | 34 (18) | 145 (19) | |
| Sexual health clinic | 101 (41) | 87 (47) | 300 (39) | |
MSM=men who have sex with men; IDU=injecting drug use.